Biogen Sues Neurimmune Over Rights to Novel Alzheimer's Bispecific Antibody Technology
• Biogen has filed a lawsuit against Neurimmune seeking declaratory judgment that their 2007 Collaboration Agreement does not give Neurimmune rights to Biogen's bispecific antibody technology for Alzheimer's disease.
• The disputed technology features a bispecific antibody that targets both the transferrin receptor on the blood-brain barrier and amyloid-beta plaques, potentially offering a novel approach to Alzheimer's treatment.
• Biogen claims the antibody is part of their proprietary Tissue-Enhanced Delivery Platform designed to help molecules cross the blood-brain barrier, which was developed independently of their collaboration with Neurimmune.
© Copyright 2025. All Rights Reserved by MedPath